These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 24685132)

  • 41. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
    Ambrogio C; Köhler J; Zhou ZW; Wang H; Paranal R; Li J; Capelletti M; Caffarra C; Li S; Lv Q; Gondi S; Hunter JC; Lu J; Chiarle R; Santamaría D; Westover KD; Jänne PA
    Cell; 2018 Feb; 172(4):857-868.e15. PubMed ID: 29336889
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer.
    Kitai H; Ebi H
    Small GTPases; 2017 Jul; 8(3):172-176. PubMed ID: 27392325
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.
    Singh A; Sweeney MF; Yu M; Burger A; Greninger P; Benes C; Haber DA; Settleman J
    Cell; 2012 Feb; 148(4):639-50. PubMed ID: 22341439
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.
    Pang X; Liu M
    Chin J Cancer; 2016 Oct; 35(1):92. PubMed ID: 27793187
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation.
    Hao J; Yang X; Ding XL; Guo LM; Zhu CH; Ji W; Zhou T; Wu XZ
    Sci Rep; 2016 Sep; 6():32809. PubMed ID: 27609096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells.
    Yoon YK; Kim HP; Song SH; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
    Cancer Lett; 2012 Mar; 316(1):77-84. PubMed ID: 22082529
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.
    Mao CQ; Xiong MH; Liu Y; Shen S; Du XJ; Yang XZ; Dou S; Zhang PZ; Wang J
    Mol Ther; 2014 May; 22(5):964-73. PubMed ID: 24496383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.
    Spreafico A; Tentler JJ; Pitts TM; Tan AC; Gregory MA; Arcaroli JJ; Klauck PJ; McManus MC; Hansen RJ; Kim J; Micel LN; Selby HM; Newton TP; McPhillips KL; Gustafson DL; Degregori JV; Messersmith WA; Winn RA; Eckhardt SG
    Clin Cancer Res; 2013 Aug; 19(15):4149-62. PubMed ID: 23757356
    [TBL] [Abstract][Full Text] [Related]  

  • 49. KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib.
    Wang G; Huang Y; Wu Z; Zhao C; Cong H; Ju S; Wang X
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30674639
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
    Dietlein F; Kalb B; Jokic M; Noll EM; Strong A; Tharun L; Ozretić L; Künstlinger H; Kambartel K; Randerath WJ; Jüngst C; Schmitt A; Torgovnick A; Richters A; Rauh D; Siedek F; Persigehl T; Mauch C; Bartkova J; Bradley A; Sprick MR; Trumpp A; Rad R; Saur D; Bartek J; Wolf J; Büttner R; Thomas RK; Reinhardt HC
    Cell; 2015 Jul; 162(1):146-59. PubMed ID: 26140595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K).
    Eder S; Arndt A; Lamkowski A; Daskalaki W; Rump A; Priller M; Genze F; Wardelmann E; Port M; Steinestel K
    Cancer Lett; 2017 Jan; 385():160-167. PubMed ID: 27793696
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.
    Jones GG; Del Río IB; Sari S; Sekerim A; Young LC; Hartig N; Areso Zubiaur I; El-Bahrawy MA; Hynds RE; Lei W; Molina-Arcas M; Downward J; Rodriguez-Viciana P
    Nat Commun; 2019 Jun; 10(1):2532. PubMed ID: 31182717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers.
    Guerra SL; Maertens O; Kuzmickas R; De Raedt T; Adeyemi RO; Guild CJ; Guillemette S; Redig AJ; Chambers ES; Xu M; Tiv H; Santagata S; Jänne PA; Elledge SJ; Cichowski K
    Cancer Cell; 2020 May; 37(5):705-719.e6. PubMed ID: 32243838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.
    Ebi H; Faber AC; Engelman JA; Yano S
    Cancer Sci; 2014 May; 105(5):499-505. PubMed ID: 24612015
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oncogenic ERBB3 mutations in human cancers.
    Jaiswal BS; Kljavin NM; Stawiski EW; Chan E; Parikh C; Durinck S; Chaudhuri S; Pujara K; Guillory J; Edgar KA; Janakiraman V; Scholz RP; Bowman KK; Lorenzo M; Li H; Wu J; Yuan W; Peters BA; Kan Z; Stinson J; Mak M; Modrusan Z; Eigenbrot C; Firestein R; Stern HM; Rajalingam K; Schaefer G; Merchant MA; Sliwkowski MX; de Sauvage FJ; Seshagiri S
    Cancer Cell; 2013 May; 23(5):603-17. PubMed ID: 23680147
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.
    Mirzoeva OK; Collisson EA; Schaefer PM; Hann B; Hom YK; Ko AH; Korn WM
    Mol Cancer Ther; 2013 Oct; 12(10):2213-25. PubMed ID: 23918833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in
    Jansen RA; Mainardi S; Dias MH; Bosma A; van Dijk E; Selig R; Albrecht W; Laufer SA; Zender L; Bernards R
    Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2319492121. PubMed ID: 38377196
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.
    Azoitei N; Hoffmann CM; Ellegast JM; Ball CR; Obermayer K; Gößele U; Koch B; Faber K; Genze F; Schrader M; Kestler HA; Döhner H; Chiosis G; Glimm H; Fröhling S; Scholl C
    J Exp Med; 2012 Apr; 209(4):697-711. PubMed ID: 22451720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. STK33 kinase activity is nonessential in KRAS-dependent cancer cells.
    Babij C; Zhang Y; Kurzeja RJ; Munzli A; Shehabeldin A; Fernando M; Quon K; Kassner PD; Ruefli-Brasse AA; Watson VJ; Fajardo F; Jackson A; Zondlo J; Sun Y; Ellison AR; Plewa CA; San MT; Robinson J; McCarter J; Schwandner R; Judd T; Carnahan J; Dussault I
    Cancer Res; 2011 Sep; 71(17):5818-26. PubMed ID: 21742770
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
    Tolcher AW; Khan K; Ong M; Banerji U; Papadimitrakopoulou V; Gandara DR; Patnaik A; Baird RD; Olmos D; Garrett CR; Skolnik JM; Rubin EH; Smith PD; Huang P; Learoyd M; Shannon KA; Morosky A; Tetteh E; Jou YM; Papadopoulos KP; Moreno V; Kaiser B; Yap TA; Yan L; de Bono JS
    Clin Cancer Res; 2015 Feb; 21(4):739-48. PubMed ID: 25516890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.